Who are Temozolomide + TACE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Paraplatin, Cytoxan (Lyophilized), Standard of Care: Cyclophosphamide, Platinum-Based Chemotherapy, Cyclophosphamide (CYC), CYC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/temozolomide-tace.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Temozolomide + TACE — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Temozolomide + TACE (Temozolomide + TACE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: alkylating agent. Area: Oncology.

phase 3 alkylating agent Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Temozolomide + TACE (Temozolomide + TACE) — Taizhou Hanzhong biomedical co. LTD. Temozolomide is an alkylating agent that works by interfering with DNA replication in cancer cells, while TACE is a minimally invasive procedure that involves the insertion of a catheter to deliver chemotherapy directly to the tumor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Temozolomide + TACE TARGET	Temozolomide + TACE	Taizhou Hanzhong biomedical co. LTD	phase 3	alkylating agent
Paraplatin	Carboplatin	MYLAN SEIYAKU Ltd	marketed	Platinum-containing alkylating agent	DNA	1989-01-01
Cytoxan (Lyophilized)	cyclophosphamide	Baxter	marketed	Alkylating agent	Tumor cell DNA	1959-01-01
Standard of Care: Cyclophosphamide	Standard of Care: Cyclophosphamide	H. Lee Moffitt Cancer Center and Research Institute	marketed	Alkylating agent	DNA
Platinum-Based Chemotherapy	Platinum-Based Chemotherapy	Genprex, Inc.	marketed	Platinum-based alkylating agent	DNA
Cyclophosphamide (CYC)	Cyclophosphamide (CYC)	Hansa Biopharma AB	marketed	Alkylating agent	DNA
CYC	CYC	Italian Sarcoma Group	marketed	Alkylating agent	DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2035-06-26 — Cytoxan (Lyophilized) · 9662342 · Formulation · US
2035-07-13 — Cytoxan (Lyophilized) · 10849916 · Formulation · US
2035-12-01 — Cytoxan (Lyophilized) · 11382923 · Formulation · US
2036-02-15 — Cytoxan (Lyophilized) · 12329767 · Formulation · US
2036-02-15 — Cytoxan (Lyophilized) · 10993952 · Formulation · US

Sponsor landscape (alkylating agent class)

Alliance for Clinical Trials in Oncology · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Radiation Therapy Oncology Group · 1 drug in this class
Taizhou Hanzhong biomedical co. LTD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Temozolomide + TACE — Competitive Intelligence Brief. https://druglandscape.com/ci/temozolomide-tace. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing